- ￥800 - 4130
- Solarbio
- 北京
- IB0780
- 2026年02月04日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 技术资料
- 保存条件：
Powder:-20℃，2 years;Insolvent(母液):-20℃，6 months;-80℃，1 year
- 保质期：
Powder:-20℃，2 years;Insolvent(母液):-20℃，6 months;-80℃，1 year
- 英文名：
BI 2536
- 库存：
现询
- 供应商：
北京索莱宝科技有限公司
- CAS号：
755038-02-9
- 规格：
100mg/50mg/25mg/10mM*1mL in DMSO/10mg/5mg
| 规格： | 100mg | 产品价格： | ￥4130.0 |
|---|---|---|---|
| 规格： | 50mg | 产品价格： | ￥2290.0 |
| 规格： | 25mg | 产品价格： | ￥1378.0 |
| 规格： | 10mM*1mL in DMSO | 产品价格： | ￥1200.0 |
| 规格： | 10mg | 产品价格： | ￥1244.0 |
| 规格： | 5mg | 产品价格： | ￥800.0 |
| 基本信息 | |
| CAS | No.755038-02-9 |
| 英文名称 | BI 2536 |
| 别名 | 4-[[(7R)-8-环戊基-7-乙基-5，6，7，8-四氢-5-甲基-6-氧代-2-喋啶基]氨基]-3-甲氧基-N-(1-甲基-4-Piperi-dine基)苯甲酰胺 |
| 分子式 | C28H39N7O3 |
| 分子量 | 521.66 |
| 溶解性 | Soluble in DMSO |
| 纯度 | ≥98% |
| 外观(性状) | White to light yellow Solid |
| 储存条件 | Powder:-20℃，2 years;Insolvent(母液):-20℃，6 months;-80℃，1 year |
| EC | EINECS 1308068-626-2 |
| MDL | MFCD10565924 |
| SMILES | O=C1[C@H](N(C2=C(N1C)C=NC(NC3=CC=C(C(NC4CCN(C)CC4)=O)C=C3OC)=N2)C5CCCC5)CC |
| 靶点 | Polo-like Kinase (PLK);BRD4;IFNβ |
| 通路 | Cell Cycle;Immunology & Inflammation |
| 背景说明 | BI 2536是 PLK1 和 BRD4 的双抑制剂。 |
| 生物活性 | BI 2536 is a dual PLK1 and BRD4 inhibitor with IC50s of 0.83 and 25 nM, respectively[1]. BI-2536 suppresses IFNB (encoding IFN-β) gene transcription[4]. |
| In Vitro | Exceeding a 100-fold concentration range starting at 10 nM，BI 2536 causes HeLa cells to accumulate with a 4N DNA content，indicative of a cell-cycle block in either G2 phase or mitosis. In addition to HeLa cells，BI 2536 potently inhibits the proliferation of a panel of 32 human cancer cell lines，representing diverse organ derivations(including carcinomas of the breast，colon，lung，pancreas，and prostate，melanomas，and hematopoietic cancers)and varied patterns of tumor suppressor or oncogene mutations(including RB1，TP53，PTEN，andKRAS status). The half-maximal effective concentration(EC50)values in this cell panel ranged 2-25 nM，whereas a concentration of 100 nM of BI 2536 is typically sufficient for inducing a complete mitotic arrest. The proliferation of exponentially growing hTERT-RPE1，human umbilical vein endothelial cells(HUVECs)，and normal rat kidney(NRK)cells is blocked at EC50values ranging 12-31 nM，indicating a comparable sensitivity of cycling nontransformed cells to BI 2536[3]. |
| 细胞实验 | BI 2536(40-50 mg/kg，i.v.)blocks the growth of human cancer xenografts in immunodeficient，nu/nu mice. Consecutive cycles of 40-50 mg/kg BI 2536 given i.v. once or twice per week are found to be highly efficacious in diverse xenograft models，such as the HCT 116 colon cancer with complete tumor suppression with the twice per week schedule(treated versus the control(T/C)value 0.3%)and a T/C value of 16% with once per week treatment; both schedules are well-tolerated，as judged by clinical signs and absence of major body-weight changes[3]. |
| 细胞实验 | Cell proliferation assays are performed by incubation in the presence of various concentrations of BI 2536(10 nM-1 μM)for 72 hr，and cell growth is assessed by the measurement of Alamar Blue dye conversion in a fluorescence spectrophotometer. Effective concentrations at which cellular growth is inhibited by 50%(EC50)are extrapolated from the dose-response curve fit[3]. |
| 动物实验 | Female BomTac:NMRI-Foxn1nu mice are grafted subcutaneously with HCT 116 colon-carcinoma，NCI-H460，or A549 lung-carcinoma cells by subcutaneous injection，respectively，of 2×106，1×106，and 1×107 cells into the flank of each mouse. When tumors reached a volume of approximately 50 mm3，animals are pair-matched into treatment and control groups of ten mice each. In regression experiments，treatment is not initiated until the mean tumor volume reached 500 mm3. BI 2536 is injected intravenously into the tail vein at the indicated dose and schedule. The administration volume is 10 mL per kg body weight. Tumor volumes are determined three times a week with a caliper. The results are converted to tumor volume(mm3)by the following formula: length×width2×π/6. The weight of the mice is determined as an indicator of tolerability on the same days. For statistical analysis，the treatment group is compared with the vehicle control group in a one-sided(decreasing)exact Wilcoxon test.[3] |
| 数据来源文献 | [1]. Lénárt P， et al. The Small-Molecule Inhibitor BI 2536 Reveals Novel Insights into Mitotic Roles of Polo-like Kinase 1. Curr Biol. 2007 Feb 20;17(4):304-15. [2]. Chen L， et al. BRD4 Structure-Activity Relationships of Dual PLK1 Kinase/BRD4 Bromodomain Inhibitor BI-2536. ACS Med Chem Lett. 2015 May 18;6(7):764-9. [3]. Steegmaier M， et al. BI 2536， a Potent and Selective Inhibitor of Polo-like Kinase 1， Inhibits Tumor Growth In Vivo. Current Biology (2007)， 17(4)， 316-322. [4]. Malik N， et al. Suppression of IFN β gene transcription by inhibitors of bromodomain and extra-terminal (BET) family members. Biochem J. 2015 Jun 15;468(3):363-72. |
| 单位 | 瓶 |
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
技术资料暂无技术资料 索取技术资料
IB0780 BI 2536 细胞周期 索莱宝
￥800 - 4130
